(CIDRAP News) The avian influenza virus long established in Southeast Asia has reached Europe's doorstep, with confirmation today that a lethal virus in Turkey is H5N1 and that an H5 strain in Romania is still being subtyped.
(CIDRAP News) – The European Union (EU) has approved Novartis's seasonal influenza vaccine, Optaflu, putting the Swiss company in a position to become the first to market a flu vaccine grown in cell culture rather than eggs.
Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.
(CIDRAP News) A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culturea combination of techniques that entails some risk but may boost immune response and shorten production time.
(CIDRAP News) Australian authorities have approved an H5N1 avian influenza vaccine made by the Australian-based pharmaceutical company CSL Limited, giving the country a home-grown defensive tool if the virus evolves into a pandemic strain.
(CIDRAP News) – An H5N1 influenza vaccine made by Baxter International could become the first cell culture–based H5N1 influenza vaccine to be approved for marketing, following its endorsement by a committee of the European Medicines Agency (EMEA) last week.
Recommendations of the Committee for Medicinal Products for Human Use (CHMP) are usually followed by the EMEA within a few months.
Editor's note: This story was updated Feb 27 to include more information about an intradermal vaccine that Sanofi Pasteur is developing for the US market.
(CIDRAP News) The European Union has approved the first influenza vaccine injected with a shallow needle prick into the skin instead of a jab all the way into muscle, according to Sanofi Pasteur, the vaccine's manufacturer.